Application of bambuterol hydrochloride in patients with acute exacerbation of chronic obstructive pulmonary disease
Objective To investigate the application of bambuterol hydrochloride in patients with acute exacerbation of chronic obstructive pulmonary disease.Methods A total of 68 patients with acute exacerbation of chronic obstructive pulmonary disease from May 2023 to August 2023 were divided into the control group and the observation group according to random number table method.The control group(34 cases)received moxifloxacin hydrochloride,and the observation group(34 cases)received moxifloxacin hydrochloride combined with bambuterol hydrochloride.The clinical efficacy and adverse reactions of the two groups were compared,and the levels of coagulation function indexes before and after treatment were compared.Results Before treatment,there was no significant difference in the level of coagulation function between the control group and the observation group(P＞0.05).After treatment,FIB and DD levels in both groups were significantly lower than before treatment,and compared with the control group,the observation group was significantly lower(P＜0.05),and PT,TT and APTT levels were significantly increased,and compared with the control group,the observation group was significantly higher(P＜0.05).The incidence of adverse reactions was 8.82%in the control group and 17.65%in the observation group,the difference was not statistically significant(P＞0.05).The clinical effective rate of the control group and the observation group were 73.53%and 94.12%,respectively,and the observation group was significantly higher(P＜0.05).Conclusion The treatment of bambuterol hydrochloride can significantly improve the coagulation function of patients with acute exacerbation of chronic obstructive pulmonary disease,so as to improve the therapeutic effect.
万方数据
维普
